|
|
|
|
BRIEF: Alexion Pharmaceuticals A Takeover Target?
Shares of Alexion Pharmaceuticals Inc.were up 98 cents to $53.83 Tuesday after Goldman Sachs Group identified the Cheshire drugmaker as a possible takeover target for pharmaceutical firms trying to expand their offerings. Alexion's drug, Soliris,...
|
|
|
Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma
Asthma: LABAs should not be used aloneThe U.S.Food and Drug Administration today announced that drugs in the class of long-acting beta ag...Revisional bariatric surgery linked to higher risk of complicationsRevisional bariatric surgery appears to be...
|
|
|
Alexion Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 20:07:07 - Alexion Pharmaceuticals, Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Alexion Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare...
|
|
|
Alexion Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market
www.companiesandmarkets.com/Summary-Company-Profile/alexion-phar ..Alexion Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the companys...
|
|
|
Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 201
- Global Day of Recognition Underscores Need to Develop, and Provide Access to, Orphan Therapies - Rare Disease Day, established by EURORDIS in 2008, seeks to increase the visibility of rare diseases, give hope and information to patients, coordinate policy...
|
|
|
Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 201
Let the jobs come to you!Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day,...
|
|
|
World's Costliest Medicine, Soliris , Costs (Dollor) 400k Per Year
The world's priciest medicine, Soliris, costs an astonishing 409,500 dollars World's Costliest Medicine, Soliris , Costs (Dollor) 400k Per Year.
|
|
|
Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2010
CHESHIRE, Conn.& SMITHFIELD, R.I.-- (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the...
|
|
|
Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness
Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.To reduce...
|
|
|
Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 201
Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.Rare...
|
|
|
Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2010
CHESHIRE, Conn.& SMITHFIELD, R.I.(BUSINESS WIRE) Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third...
|
|
|
Alexion Appoints Andreas Rummelt to its Board of Directors
- Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN) today announced that Andreas Rummelt, Ph. D., has been appointed a Director of Alexion, effective immediately. About Andreas Rummelt Dr. Rummelt has more than 25 years of experience in the pharmaceutical...
|
|
|
Alexion Pharmaceuticals appoints new board member
Alexion Pharmaceuticals, a biopharmaceutical company, has appointed Andreas Rummelt to its board of directors.Dr Rummelt was a member of the executive committee of Novartis from 2006 to 2010, where he most recently served as group head of quality assurance...
|
|
|
Alexion Appoints Andreas Rummelt to its Board of Directors
CHESHIRE, Conn.-- (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN) today announced that Andreas Rummelt, Ph.D., has been appointed a Director of Alexion, effective immediately. About Andreas Rummelt Dr. Rummelt has more than 25 years of...
|
|
|
Alexion Appoints Andreas Rummelt to its Board of Directors
Companies mentioned in this article: Alexion Pharmaceuticals, Inc.CHESHIRE, Conn. -- (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Andreas Rummelt, Ph.D., has been appointed a Director of Alexion, effective...
|
|
|
Alexion Appoints Andreas Rummelt to its Board of Directors
Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN) today announced that Andreas Rummelt, Ph. D., has been appointed a Director of Alexion, effective immediately. About Andreas Rummelt Dr. Rummelt has more than 25 years of experience in the pharmaceutical...
|
|
|
Alexion Appoints Andreas Rummelt to its Board of Directors
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN) today announced that Andreas Rummelt, Ph.D., has been appointed a Director of Alexion, effective immediately. Rummelt has more than 25 years of experience in the pharmaceutical...
|
|
|
Alexion Appoints Andreas Rummelt to its Board of Directors
CHESHIRE, Conn.(BUSINESS WIRE) Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN) today announced that Andreas Rummelt, Ph.D., has been appointed a Director of Alexion, effective immediately. About Andreas Rummelt Dr. Rummelt has more than 25 years of...
|
|
|
The worlds most expensive drug: Alexion Pharmaceuticals Soliris, at $409,500 per year
Forbes magazine survey finds top nine drugs, all costing $200,000 annually Alexion Pharmaceuticals (Cheshire, CT), on the market for two years with Soliris (eculizumab), gets the prizeif thats the right termfor the worlds most expensive drug, according to...
|
|
|
The worlds most expensive drug: Alexion Pharmacueticals Soliris, at $409,500 per year
Forbes magazine survey finds top nine drugs, all costing $200,000 annually Alexion Pharmaceuticals (Cheshire, CT), on the market for two years with Soliris (eculizumab), gets the prizeif thats the right termfor the worlds most expensive drug, according to...
|
|
|
Which drugs get the most-expensive crown?
If you wonder why Big Pharma is so interested in drugs for rare diseases, here's a possibility: High prices.In fact, a new Forbes survey finds that the cost of meds targeted to small groups of patients with serious genetic disorders dwarfs the prices of...
|
|
|
Alexion posts $295M 4Q profit
Alexion Pharmaceuticals Inc.in Cheshire saw fourth-quarter earnings climb more than 17-fold from a year earlier, propelled largely by a one-time tax benefit stemming from development of its treatment for a rare blood disorder. The developer and marketer of...
|
|
|
Alexion Pharmaceuticals (NASDAQ: ALXN) Posts Rise in 4Q Profit
Rochester, New York 2/12/2010 10:35 PM GMT (TransWorldNews) Alexion Pharmaceuticals Inc.(NASDAQ: ALXN) reported Thursday that its fourth-quarter profit rose due to hefty tax benefit and sales of the blood disorder treatment Soliris, according to...
|
|
|
Alexion Reports Fourth Quarter and Full Year 2009 Results
Soliris Net Product Sales Increased 49% to $386.8 Million in 2009 Continued Strong Uptake of Soliris By New Patients in U.S.and Europe in Q4 Soliris Development Programs Advance in aHUS and Transplant Fourth Quarter 2009 Financial...
|
|
|
Alexion Pharmaceuticals' 4th-quarter profit jumps on tax benefit, boost in Soliris sales
CHESHIRE, CONN.Alexion Pharmaceuticals Inc. said Thursday its fourth-quarter profit surged on a hefty tax benefit and sales of the blood disorder treatment Soliris, its only marketed product. Including a tax gain of $214.5 million, the company...
|
